Brief: Heidelberg Pharma: Partner Magenta Therapeutics Exercises Option To Further Develop Target Molecule

Heidelberg Pharma AG

11/10/2018 11:02

Oct 11 (Reuters) - Heidelberg Pharma AG  WL6G.DE :
    * PARTNER MAGENTA THERAPEUTICS EXERCISES OPTION TO FURTHER
DEVELOP
A TARGET MOLECULE AS ANTIBODY TARGETED AMANITIN CONJUGATE
    * HEIDELBERG PHARMA RECEIVES AN UNDISCLOSED MILESTONE
PAYMENT IN
RETURN
    * WOULD BE ELIGIBLE TO RECEIVE CLINICAL DEVELOPMENT,
REGULATORY
AND SALES-RELATED MILESTONE PAYMENTS

Source text for Eikon:  ID:nEQ92gSFba 
Further company coverage:  WL6G.DE 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))